IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

IN8bio (Nasdaq: INAB) granted inducement stock options to two new employees to purchase an aggregate of 11,800 shares, with a grant date of April 1, 2026 under Nasdaq Listing Rule 5635(c)(4).

The nonqualified options vest over four years (25% after one year, then 36 equal monthly installments), were approved by the Compensation Committee, and were issued outside the company’s 2023 Equity Incentive Plan as an inducement to employment.

AI-generated analysis. Not financial advice.

News Market Reaction – INAB

-2.08%

1 alert

-2.08% News Effect

On the day this news was published, INAB declined 2.08%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Current price: $1.44 Price change 24h: 2.86% Inducement options: 11,800 shares +5 more

8 metrics

Current price $1.44 Pre-news trading level

Price change 24h 2.86% Move prior to inducement grant announcement

Inducement options 11,800 shares Aggregate nonqualified stock options for two new employees

Vesting schedule 4 years 25% at first anniversary, then 36 monthly installments

Grant date April 1, 2026 Inducement option grant date under Nasdaq Rule 5635(c)(4)

Registered shares 14,384,052 shares Resale registration for PIPE and pre-funded warrant shares

Net proceeds $18.6 million Initial closing of Dec 2025 private placement (per shelf summary)

Exercise price (warrants) $0.0001 per share Pre-Funded Warrants exercise price under resale registration

Market Reality Check

Price: $1.5800 Vol: Volume 17,892 is well bel...

low vol

$1.5800 Last Close

Volume Volume 17,892 is well below the 20-day average of 83,896 (about 0.21x typical activity). low

Technical Shares at $1.44 are trading below the 200-day MA of $2.01 and 75% under the 52-week high of $5.817.

Peers on Argus

INAB gained 2.86% while close peers were mixed: RNAZ -2.49%, CYCCP -5.61%, PCSA ...

INAB gained 2.86% while close peers were mixed: RNAZ -2.49%, CYCCP -5.61%, PCSA -3.48%, APRE +0.7%, MBIO +4.36%. This pattern points to a stock-specific move rather than a sector-wide rotation.

Historical Context

5 past events · Latest: Mar 12 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 12	Earnings & pipeline	Positive	-1.1%	Reported 2025 results, strengthened cash and positive GBM data, but shares fell.
Feb 24	Conference appearance	Positive	+2.6%	Announced TD Cowen conference presentation and investor meetings; stock rose.
Feb 09	Leadership promotion	Positive	+0.5%	Promoted COO to President, reinforcing leadership for γδ T cell programs.
Feb 03	Multiple conferences	Positive	+1.5%	Outlined upcoming investor and scientific conference presentations on GBM program.
Jan 12	Clinical data update	Positive	-7.2%	Reported improved GBM survival and good tolerability, yet shares declined notably.

Pattern Detected

Positive clinical and financing news has sometimes seen negative or muted next-day price reactions.

Recent Company History

Over the last six months, IN8bio has focused on advancing its γδ T cell pipeline, reporting encouraging glioblastoma data and strengthening its balance sheet. A January Phase 1/2 update showed improved survival versus standard of care, while March 10-K and earnings disclosures highlighted a longer cash runway but also a going concern warning. Conference and leadership updates in February underscored ongoing business development and operational continuity. Today’s Nasdaq Rule 5635(c)(4) inducement option grant fits into this pattern of routine corporate and equity compensation actions.

Regulatory & Risk Context

Active S-3 Shelf

Shelf Active

Active S-3 Shelf Registration 2026-01-20

An effective S-3 resale registration dated Jan 20, 2026 covers up to 14,384,052 previously issued or issuable shares, including PIPE and pre-funded warrant shares. The company is not selling shares under this prospectus and receives no proceeds from selling stockholders, indicating potential secondary selling overhang rather than primary capital raising.

Market Pulse Summary

This announcement details a small Nasdaq Rule 5635(c)(4) inducement grant of 11,800 nonqualified opt...

Analysis

This announcement details a small Nasdaq Rule 5635(c)(4) inducement grant of 11,800 nonqualified options to two new employees, vesting over 4 years. It follows recent governance, compensation, and financing disclosures, including a new equity plan proposal and a resale registration for previously issued shares. Investors may watch how ongoing option grants and registered resale shares interact with IN8bio’s capital needs and prior going concern language in its 10-K.

Key Terms

nasdaq listing rule 5635(c)(4), nonqualified stock options, equity incentive plan, vesting

4 terms

nasdaq listing rule 5635(c)(4) regulatory

"as an inducement material to the new employees... in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

nonqualified stock options financial

"granted two employees nonqualified stock options to purchase an aggregate of 11,800 shares"

A nonqualified stock option is a company-issued right that lets an employee or contractor buy shares later at a preset price, like a coupon to purchase stock regardless of the market price. It matters to investors because when the option is used the recipient owes ordinary-income tax on the difference between market and preset price, which affects the holder’s financial decisions and can change the company’s share count and reported expenses.

equity incentive plan financial

"granted outside of the Company’s 2023 Equity Incentive Plan, with a grant date of April 1, 2026"

An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.

vesting financial

"The stock options will vest over a four-year period, with 25% of each of the options vesting on the first anniversary"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

AI-generated analysis. Not financial advice.

NEW YORK, April 03, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (the “Company”) (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative γδ T cell therapies for cancer and autoimmune diseases, today announced that the Compensation Committee of the Company’s Board of Directors granted two employees nonqualified stock options to purchase an aggregate of 11,800 shares of its common stock. The awards were approved by the Compensation Committee of the Company’s Board of Directors and were granted outside of the Company’s 2023 Equity Incentive Plan, with a grant date of April 1, 2026, as an inducement material to the new employees entering into employment with the Company, in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock options will vest over a four-year period, with 25% of each of the options vesting on the first anniversary of such employee’s start date, with the remainder of the options vesting in thirty-six (36) equal monthly installments thereafter, subject to continued employment on each vesting date.

About IN8bio

IN8bio is a clinical-stage biopharmaceutical company developing γδ T cell and γδ T cell engager (TCE) product candidates to address unmet medical needs. γδ T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The Company’s lead programs consist of INB-100, an allogeneic γδ T cell candidate for adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation, and INB-200/400, an autologous genetically modified γδ T cell candidate for newly diagnosed Glioblastoma (GBM). The Company is also developing a novel γδ T cell engager platform, INB-600, for potential oncology and autoimmune indications. For more information about IN8bio, visit www.IN8bio.com.

Investors and Corporate Contact:

IN8bio, Inc.
Patrick McCall
646.933.5603
pfmccall@IN8bio.com

Media Contact
Kimberly Ha
KKH Advisors
917.291.5744
kimberly.ha@kkhadvisors.com

FAQ

What did IN8bio (INAB) announce on April 3, 2026 about new employee equity?

IN8bio announced nonqualified stock options totaling 11,800 shares for two new employees, granted April 1, 2026. According to IN8bio, the awards were approved by the Compensation Committee and issued as inducements under Nasdaq Listing Rule 5635(c)(4).

How do the IN8bio (INAB) inducement stock options vest and when do they start to vest?

The options vest over four years, with 25% vesting on the first anniversary and the remainder in 36 equal monthly instalments. According to IN8bio, vesting is contingent on continued employment on each vesting date.

Were the IN8bio (INAB) stock options granted under the company’s 2023 Equity Incentive Plan?

No, the options were granted outside the 2023 Equity Incentive Plan as inducement awards. According to IN8bio, grants were made specifically under Nasdaq Listing Rule 5635(c)(4) to attract the new hires.

How many employees received inducement grants from IN8bio (INAB) and what is the aggregate size?

Two employees received inducement option awards totaling 11,800 shares aggregated. According to IN8bio, the Compensation Committee approved the grants as material inducements tied to employment.

What rule did IN8bio (INAB) reference for its April 1, 2026 inducement option grants?

IN8bio referenced Nasdaq Listing Rule 5635(c)(4), which permits outside-plan inducement awards for new hires. According to IN8bio, the grants complied with that rule and were approved by the Compensation Committee.